{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:19:04Z","timestamp":1789579144786,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["06122A10"],"award-info":[{"award-number":["06122A10"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neulet.2025.138349","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:06:08Z","timestamp":1754665568000},"page":"138349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer\u2019s disease model"],"prefix":"10.1016","volume":"865","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-6793","authenticated-orcid":false,"given":"Tangui","family":"Maurice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neulet.2025.138349_b0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/13872877241289602","article-title":"The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors","volume":"102","author":"Moss","year":"2024","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.neulet.2025.138349_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/physrev.00030.2022","article-title":"Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease","volume":"104","author":"Perluigi","year":"2024","journal-title":"Physiol. Rev."},{"issue":"23","key":"10.1016\/j.neulet.2025.138349_b0015","doi-asserted-by":"crossref","first-page":"12613","DOI":"10.3390\/ijms252312613","article-title":"Decoding neurodegeneration: a review of molecular mechanisms and therapeutic advances in Alzheimer's, Parkinson's, and ALS","volume":"25","author":"Toader","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.neulet.2025.138349_b0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.14283\/jpad.2024.142","article-title":"Plasma biomarkers of Alzheimer's disease and neurodegeneration according to sociodemographic characteristics and chronic health conditions","volume":"11","author":"Zheng","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.neulet.2025.138349_b0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3233\/JAD-201274","article-title":"A Review of brain atrophy subtypes definition and analysis for Alzheimer's disease heterogeneity studies","volume":"80","author":"Zhang","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.neulet.2025.138349_b0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","article-title":"Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy","volume":"23","author":"Belder","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neulet.2025.138349_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108398","article-title":"The pathomimetic oA\u03b225-35 model of Alzheimer's disease: potential for screening of new therapeutic agents","volume":"245","author":"Canet","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.neulet.2025.138349_b0040","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14814","article-title":"The selective butyrylcholinesterase inhibitor UW-MD-95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease","volume":"30","author":"Carles","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.neulet.2025.138349_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12640-017-9838-2","article-title":"Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex i activity in physiological condition but protect against pathological oxidative stress","volume":"35","author":"Goguadze","year":"2019","journal-title":"Neurotox. Res."},{"issue":"8","key":"10.1016\/j.neulet.2025.138349_b0050","first-page":"463","article-title":"Mitochondrial protection by the mixed muscarinic\/\u03c31 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A\u03b225-35 peptide-injected mice, a nontransgenic Alzheimer's disease model","volume":"20","author":"Lahmy","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.neulet.2025.138349_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","article-title":"Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease","volume":"82","author":"Salloway","year":"2025","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.neulet.2025.138349_b0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.neulet.2025.138349_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100016","article-title":"Blarcamesine for the treatment of early Alzheimer's disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial","volume":"12","author":"Macfarlane","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.neulet.2025.138349_b0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0269881110379286","article-title":"Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma 1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative","volume":"25","author":"Villard","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neulet.2025.138349_b0075","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.neulet.2025.138349_b0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cells8030211","article-title":"Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo","volume":"8","author":"Christ","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neulet.2025.138349_b0085","unstructured":"Grimmer T., M.N. Sabbagh, S. Macfarlane, W.R. Chezem, K. Jin, J.C. Lopez Talavera, C.U. Missling, Phase IIb\/III ATTENTION-AD study: Over three years of continuous treatment with oral blarcamesine continues to significantly benefit early Alzheimer\u2019s disease patients. in AD\/PD-2025. 2025. Vienna, Austria."},{"key":"10.1016\/j.neulet.2025.138349_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104923","article-title":"Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the \u201cADAMANT\u201d randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial","volume":"99","author":"Cullen","year":"2024","journal-title":"EBioMedicine"},{"issue":"s1","key":"10.1016\/j.neulet.2025.138349_b0095","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.3233\/JAD-231238","article-title":"Tau immunotherapies for Alzheimer's disease and related tauopathies: status of trials and insights from preclinical studies","volume":"101","author":"Sigurdsson","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neulet.2025.138349_b0100","doi-asserted-by":"crossref","unstructured":"Reddi Sree R., M. Kalyan, N. Anand, S. Mani, V.R. Gorantla, M.K. Sakharkar, B.J. Song, S.B. Chidambaram, Newer therapeutic approaches in treating Alzheimer's disease: a comprehensive review. ACS Omega 10 (6) (2025) 5148-5171. doi:10.1021\/acsomega.4c05527.","DOI":"10.1021\/acsomega.4c05527"},{"issue":"2","key":"10.1016\/j.neulet.2025.138349_b0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0976-500X.72351","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"1","author":"Kilkenny","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"2","key":"10.1016\/j.neulet.2025.138349_b0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","article-title":"Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction","volume":"706","author":"Maurice","year":"1996","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neulet.2025.138349_b0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.gendis.2023.02.051","article-title":"E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease","volume":"11","author":"Zhang","year":"2024","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.neulet.2025.138349_b0120","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184656","article-title":"APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease","volume":"135","author":"Tian","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neulet.2025.138349_b0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-319-50174-1_15","article-title":"Role of \u03c31 receptors in learning and memory and Alzheimer's disease-Type dementia","volume":"964","author":"Maurice","year":"2017","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439402500237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439402500237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:59:56Z","timestamp":1762289996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030439402500237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"alternative-id":["S030439402500237X"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2025.138349","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer\u2019s disease model","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2025.138349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"138349"}}